Activity of BAL 4815 against filamentous fungi

被引:16
作者
de la Escalera, C. Martin [1 ]
Aller, A. I. [1 ]
Lopez-Oviedo, E. [1 ]
Romero, A. [1 ]
Martos, A. I. [1 ]
Canton, E. [2 ]
Peman, J. [2 ]
Martos, P. Garcia [3 ]
Martin-Mazuelos, E. [1 ]
机构
[1] Hosp Univ Valme, Serv Microbiol & Parasitol, Seville, Spain
[2] Hosp La Fe, E-46009 Valencia, Spain
[3] Hosp Puerta Mar, Cadiz 110009, Spain
关键词
Aspergillus; triazoles; antifungals;
D O I
10.1093/jac/dkn076
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: BAL 4815 is a new antifungal drug and it is the active component of the antifungal triazole BAL 8557 (the water-soluble precursor). We studied the in vitro fungistatic and fungicidal activities of BAL 4815 against 103 clinical isolates of filamentous fungi, including 51 isolates of Aspergillus spp. and 52 isolates of non-Aspergillus filamentous fungi. Methods: We evaluated the in vitro activity of BAL 4815 against 51 isolates of Aspergillus spp., 20 isolates of dematiaceous fungi, 18 isolates of hyaline Hyphomycetes and 14 isolates of Zygomycetes. MICs were determined following the CLSI M38-A broth microdilution method, using RPMI 1640 medium buffered to pH 7.0 with MOPS. Microdilution plates were incubated at 35 degrees C and read at 24 and 48 h (Mucorales were read at 24 h). Minimal fungicidal concentrations were also determined. Results: For all isolates, geometric mean MICs, MIC(50)s, MIC(90)s and MIC ranges (mg/L) were: Aspergillus spp., 1.67, 2, 4 and 0.5-4; dematiaceous fungi, 1.62, 1, > 8 and 0.03 to > 8; hyaline Hyphomycetes, 2.41, 2, > 8 and 0.03 to > 8; and Zygomycetes, 6.81, 8, > 8 and 0.03 to > 8. Differences in susceptibility between genera were noted. Scedosporium prolificans, Fusarium spp., Mucor spp. and Rhizopus spp. (MIC90 > 8 mg/L) were less susceptible than Aspergillus spp. (MIC90 = 4 mg/L). Conclusions: BAL 4815 has excellent in vitro activity against Aspergillus spp. and variable activity against other filamentous fungi.
引用
收藏
页码:1083 / 1086
页数:4
相关论文
共 16 条
[1]   A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients [J].
Bowden, R ;
Chandrasekar, P ;
White, MH ;
Li, X ;
Pietrelli, L ;
Gurwith, M ;
van Burik, JA ;
Laverdiere, M ;
Safrin, S ;
Wingard, JR .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) :359-366
[2]   In vitro susceptibilities of zygomycetes to conventional and new antifungals [J].
Dannaoui, E ;
Meletiadis, J ;
Mouton, JW ;
Meis, JFGM ;
Verweij, PE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :45-52
[3]   Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi [J].
Diekema, DJ ;
Messer, SA ;
Hollis, RJ ;
Jones, RN ;
Pfaller, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3623-3626
[4]   Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.:: NCCLS Collaborative Study [J].
Espinel-Ingroff, A ;
Fothergill, A ;
Peter, J ;
Rinaldi, MG ;
Walsh, TJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (09) :3204-3208
[5]   In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (03) :954-958
[6]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956
[7]  
GONZALEZ G, 2006, 16 C INT SOC HUM AN
[8]   Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival [J].
Groll, AH ;
Kurz, M ;
Schneider, W ;
Witt, V ;
Schmidt, H ;
Schneider, M ;
Schwabe, D .
MYCOSES, 1999, 42 (7-8) :431-442
[9]   Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi:: Comparison with CLSI broth microdilution method [J].
López-Oviedo, E ;
Aller, AI ;
Martín, C ;
Castro, C ;
Ramirez, M ;
Pemán, JM ;
Cantón, E ;
Almeida, C ;
Martín-Mazuelos, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :1108-1111
[10]   A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592) [J].
Manavathu, EK ;
Cutright, JL ;
Loebenberg, D ;
Chandrasekar, PH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) :229-234